These studies investigated the toxicological effects of 1,2bis(methylsulfonyl )-1-(2-chloroethyl)-2-(methylaminocarbonyl ) hydrazine, VNP40101M, a novel alkylating antitumor agent, in animals. Sprague-Dawley rats (2-10/sex/time point at each dose) and Beagle dogs (1-3/sex/time point at each dose) were treated with VNP40101M (0 [vehicle], 1, 3, 10, and 20 mg/kg in rats and 0, 0.3, 1, and 3 mg/kg in dogs), given intravenously (IV, bolus via the tail or slow push via the cephalic or saphenous vein, respectively) once daily for 5 consecutive days. Clinical signs, mortality, body weight, clinical pathology, gross necropsy, organ weights, and histopathology were evaluated for as long as 43 days in rats and 50 days in dogs. In rats, the toxic doses were found to be at 10 and 20 mg/kg, which induced mainly pulmonary toxicity and mortality. The pulmonary toxicity was re ected by an increase in lung weight; clear, pink or red uid within the thoracic cavity observed at necropsy; and histopathological evidence of alveolar edema, vascular congestion, alveolar histiocytosis, and vascular thrombi. Although some of these effects were observed in rats treated with 3 mg/kg, the incidence was low (» 7% -30%) and may be reversible (based on the time-dependent reduction in the magnitude of lung weight increases). Therefore, the maximum tolerated dose (MTD, or the maximum dose that did not induce signi cant toxicity or induced reversible toxicity) was¸3 mg/kg. VNP40101M at 1 mg/kg did not induce any toxicity, other than low incidence of alveolar edema (2/30 rats), and increased incidences of capillary ectasis/congestion and alveolar histocytosis (2-6/30 rats vs. 1/30 -36 in control rats). Therefore, the low effect level (LOEL) is considered to be 1 mg/kg in rats when given IV for 5 days. In dogs, LOEL, MTD, and toxic dose levels were comparable (based on a body weight/surface area conversion) to those in rats, except for some gastrointestinal (GI) effects (i.e., red lesion in the ileum) observed at 0.3 mg/kg (equivalent to 1 mg/kg, or similar to the LOEL in rats) and the associated effects (slight body weight loss and inappetence). For dogs treated with 1 mg/kg (equivalent to » 3 mg/kg, or MTD, in rats), VNP40101M induced the same GI effects seen in dogs treated with 0.3 mg/kg of VNP40101M. Additionally, a transient reduction in white blood cell counts was also observed. Three mg/kg (equivalent to » 10 mg/kg, or toxic dose level, in rats) was toxic to dogs, as re ected by the poor clinical condition of these dogs, which subsequently required euthanasia. In conclusion, VNP40101M, when given IV once daily for 5 consecutive days, has a LOEL of 1 mg/kg, a MTD of 3 mg/kg, and toxic doses at¸10 mg/kg in rats. The primary toxicity of VNP40101M was pulmonary toxicity and mortality. Based on an interspecies body weight/surface area conversion, VNP40101M had comparable LOEL (0.3 mg/kg), MTD (1 mg/kg), and toxic doses (¸3 mg/kg) in dogs, except that dogs appeared to be more sensitive to the GI effects of VNP40101M .
nitrosoureas. Carbamoylation inhibits various DNA repair enzymes, including O 6 -alkylguanine-DNA alkyltransferase, to enhance the antitumor effects induced by G-C crosslinkage. Carbamoylation also inhibits apoptosis, via the inhibition of caspases, to reduce the toxicity associated with nitrosoureas chemotherapy, because apoptosis causes slightly damaged cells (that could otherwise recover) to become committed to cell suicide. The minimization of the unwanted DNA lesions with VNP40101M is due to its distinct properties from the nitrosoureas. For example, the nitrosoureas produce large quantities of hydroxyethylating and vinylating entities, possibly via an internal cyclization reaction involving the N-nitroso group to produce 4,5-dihydro-1,2,3-oxadiazole . VNP40101M does not induce these reactions. Nitrosoureas also chloroethylate and hydroxyethylate the N 7 position of guanine in DNA, possibly via the formation of a cyclic nitrosooxazolidine. Once again, VNP40101M does not induce any chloro-or hydroxyethylations. Finally, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), and possibly other nitrosoureas, form a therapeutically irrelevant monofunctional nitrogen mustard (2-chloroethylamine), a very toxic chemical entity, from 2-chloroethyl isocyanate. VNP40101M does not produce any 2-chloroethyl isocyanate.
Because of the distinctive properties, VNP40101M is expected to be a better alkylating agent than nitrosoureas for cancer therapy. Indeed, VNP40101M has been shown to possess a broad spectrum of antitumor activity in murine solid and hematological tumor models, including leukemia (L1210 and P388), M109 lung carcinoma, B16F10 melanoma, C26 colon carcinoma, and U251 glioma. Furthermore, VNP40101M has been found to be effective against different versions of L1210 leukemia, including parental L1210 leukemia and L1210 leukemia resistant to BCNU, cyclophosphamide, and melphalan (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) . The antitumor potency of VNP40101M has also been found to be superior to many clinically used agents (e.g., BCNU, cyclophosphamide, melphalan, methotrexate, 6-mercaptopurine, cyclophosphamide, and doxorubicin) according to preclinical data (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) .
In spite of the attractive antitumor effects in animals, the toxicity of VNP40101M has not been thoroughly investigated. Accordingly, the objective of these studies was to perform a systematical toxicological evaluation of VNP40101M in rats and dogs.
MATERIALS AND METHODS

Materials
VNP40101M Injection (Vion Pharmaceuticals, Inc.) is a 10-ml injectable formulation, containing 5 mg of VNP40101M/ ml of formulation (0.3 ml of ethyl alcohol [anhydrous, United States Pharmacopeia, USP], and 0.7 ml of polyethylene glycol 300 [USP] ). Vehicle, used in the control animals, had the same composition as VNP40101M Injection, except for the absence of VNP40101M .
Animals
Adult laboratory-bred albino rats (Sprague-Dawley Crl:CD, Charles River Laboratories, Kingston, NY; »170 to 350 g body weight, »8 to 13 weeks of age of both sexes) and young adult laboratory bred Beagle dogs (Marshall Farms, North Rose, NY; »8 to 10 kg body weight, »8 to 14 months old of both sexes) were used. The animals were individually housed in stainless steel cages. Food (Certi ed Rodent Chow and Canine Diet) was sourced from PMI Feeds, Inc., Richmond, IN, and tap water was available ad libitum. The rooms were well ventilated (>10 air changes per hour, with 100% nonrecirculated fresh air), with controlled temperature (22 ± C § 3 ± C for rats and 20 ± C § 2 ± C for dogs) and relative humidity (30%-70%). Each room had a 12-hour light/dark photoperiod. All animals were acclimated to laboratory condition for 7 to 14 days prior to study initiation. Handling and care of the animals were according to the United States Department of Agriculture Animal Welfare Act (9 CFR Parts 1, 2, and 3), and the Guidelines for Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) . All studies were conducted according to Good Laboratory Practices, and per study protocol, as described in 21 CFR 58.
Experimental Design
The evaluation of the toxicological pro les of VNP40101M was conducted in rats and dogs (Table 1) . In these animals, various doses of VNP40101M (or vehicle) were administered intravenously (IV) (since it is the route in clinical studies of cancer patients), as a bolus via the lateral tail vein in rats and as a slow push over »1 to 5 minutes via the cephalic or saphenous vein in dogs. Injections of VNP40101M or control solutions were given once daily for 5 consecutive days. Toxicity was evaluated by monitoring clinical signs, body weight, clinical pathology, gross necropsy, and organ weights at various time points (Table 2) . Histopathology was also performed in all treatment groups in rats, and in group 3b dogs (i.e., dogs treated with 1 mg/kg of VNP40101M and euthanized on day 47; see Table 2 ). The time points for the toxicology assessment were chosen based on results from preliminary studies, which indicate that these time points are appropriate for assessing potential toxicity of VNP40101M .
Assays and Measurements
Clinical pathology was evaluated by performing the serum chemistry (Monarch 2000 [Instrumentation Laboratory, Lexington, MA] ) with all reagents (Instrumentation Laboratory) and hematology assays (Bayer Technicon H 1, with all the reagents from Bayer, Tarrytown, NY). The serum chemistry assay was performed with serum isolated from »2.5 ml of blood in rats and dogs. This assay included Na, K, Cl, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase , gamma-glutamyltransferase, creatine phosphokinase, calcium, phosphorus, glucose, urea (Freireich et al. 1966) . c Euthanasia was performed on various days for detecting any time-dependent toxicity, via gross necropsy, organ weights, and histopathology evaluations.
d The 10-mg/kg rats were euthanized on day 31 (instead of the intended time point of day 43) for humane reasons, due to the poor clinical condition. Some vehicle rats (3M/3F) that were originally assigned to be euthanized on day 43 were euthanized on day 31 for obtaining time-matched control values. e The toxicity on day 29 in the 1-mg/kg rats was not evaluated because no toxicity was observed at this time point at a higher dose (i.e., 3 mg/kg). Therefore, no rats had ever been assigned for this group. f The toxicity induced by this high dose at these time points was not evaluated because severe toxicity had already been observed at a lower dose (i.e., 10 mg/kg) and at similar time points. Therefore, no rats were assigned to this group. nitrogen, creatinine, total protein, albumin, globulin, albumin/ globulin ratio, cholesterol, and triglycerides. The hematology assay was performed with EDTA-containing blood (»0.5 ml in rats and »2 ml in dogs). This assay evaluated red blood cell (RBC) count, morphology, hemoglobin concentration, hematocrit, mean corpuscular hemoglobin, mean corpuscular volume, and mean corpuscular hemoglobin concentration, white blood cell (WBC) total and differential cell counts, and platelet counts.
Gross necropsy, organ weights, and histopathology evaluations were performed. For these evaluations, animals were euthanized by exsanguination while under deep anesthesia induced with Na pentobarbital. Gross necropsy included examination of the carcass and muscular/skeletal system; all external surfaces and ori ces; cranial cavity and external surface of the brain; neck with associated organs and tissues; thoracic, abdominal, and pelvic cavities with their associated organs and tissues; and injection site. For organ weight determination, the weight of the following organs were determined: adrenals, brain, epididymides, heart, kidneys, liver, lungs, ovaries, pituitary, spleen, testes, thymus, and thyroid with parathyroids. For histopathology, the following tissues were preserved in neutral-buffered 10% formalin: cardiovascular tissues (aorta and heart), digestive tissues ( vesicles, ovaries, uterus, cervix, and vagina), endocrine tissues (adrenals, pituitary, and thyroid/parathyroids), skin/musculoskeletal tissues (skin, mammary gland, bone [femoral head], and skeletal muscle [thigh]), nervous/special sense tissues (eyes with optic nerve, sciatic nerve, brain, and spinal cord [thoracic]), gross lesions, and injection site. Eyes and testes were preserved in 3% glutaraldehyde and Bouin's solution, respectively, for optimum xation. All preserved tissues were embedded in paraf n, slide-sectioned, and stained with hematoxylin and eosin. Bone marrow smears, collected at necropsy, were xed in methanol, and stained with Kwith Diff. The processed tissues were examined microscopically.
Assessment and Statistical Analysis
Differences among treatment groups and at various time points were analyzed using an analysis of variance (ANOVA), followed by Dunnett's t test for pairwise comparison. Differences were considered to be signi cant at p < :05.
RESULTS
Although some toxicities may occasionally occur more often in males and others occasionally more often in females, overall, there were no statistical differences in their responses to VNP40101M treatment between males and females. Accordingly, the results from males and females in both the rat and dog studies were combined when evaluating the effects induced by VNP40101M.
Toxicology Studies of VNP40101M in Rats Mortality and Unscheduled Euthanasia
VNP40101M at 1 or 3 mg/kg did not induce any mortality (Table 3) . At 10 mg/kg, VNP40101M induced two deaths (both males), which occurred on days 29 and 30. The six 10-mg/kg rats (3/sex) scheduled to be autopsied on day 43 were euthanized on day 31 for humane reasons, due to their poor clinical condition. Six control rats that were scheduled for euthanasia on day 43 were also autopsied on day 31 for obtaining time-matched control values. VNP40101M at 20 mg/kg did not induce any mortality. However, because these rats were monitored only for 15 days, and deaths at the lower dose occurred on or after day 29, it is highly probable that deaths would have occurred later than day 15 at 20 mg/kg.
Clinical Signs
No treatment-related clinical signs were observed at 1 or 3 mg/kg. At 10 and 20 mg/kg, treatment-related clinical signs including chromorhinorrhea , chromodacryorrhea , and staining, as well as dehydration, were observed. The incidences of these clinical signs (listed in Table 3 ) were dose-related. Polypnea was observed only in the 10-mg/kg group.
Body Weight
The body weights were not affected by 1 or 3 mg/kg of VNP40101M. However, the mean body weights were lower (or tended to be lower) on days 28 to 31 in the 10-mg/kg group, and on days 14 to 15 in the 20-mg/kg group ( Figure 1 and Table 4 ). 1 Data presented are combined results from rats euthanized at various time points at each dose level. Table 2 shows the time of euthanasia for each dose level.
2 Euthanasia was performed on day 31, which was earlier than the scheduled time of day 43, for humane reasons due to poor clinical condition.
These results indicated that as the dose increased, body weight reduction occurred sooner.
Clinical Pathology
For serum chemistry evaluation, VNP40101M at 1 or 3 mg/kg did not affect any of the serum chemistry parameters. VNP40101M at 10 and 20 mg/kg reduced, or tended to reduce, the total protein, albumin, and globulin values in a dose-related manner ( Figure 2 and Table 5 ). These reductions occurred on days 29 to 31 at 10 mg/kg and on day 15 at 20 mg/kg. The direct relationship between the dose and the onset of reduction was consistent with the pattern of the body weight reduction. For hematological evaluation, VNP40101M at 1 or 3 mg/kg did not affect RBC counts or related indices (hemoglobin and hematocrit) ( Figure 3 and Table 5 ). However, at 10 mg/kg, VNP40101M increased (or tended to increase) RBC counts and related indices (hemoglobin and hematocrit) on days 15 to 31. These increases were likely due to dehydration, which was noted in the clinical sign observation. Although not statistically significant, VNP40101M at all doses tended to reduce WBC counts in a dose-related manner on day 15, with 1 and 3 mg/kg being extremely mild ( Figure 4 and Table 5 ). At 10 mg/kg, the reduction in WBC counts was augmented over time, such that the degree of reduction was least severe on day 15, more severe on day 29, and most severe on day 31. Analysis of the relative differential WBC counts revealed increases in percent neutrophils and monocytes, and reduction in lymphocytes. Other hematological parameters were not affected by VNP40101M at any dose level.
Organ Weights
VNP40101M at 1 or 3 mg/kg did not affect any absolute organ weights (when compared to control rats), except for an increase in the lung weights in the 3 mg/kg group on days 29 and 43 (Figure 5 and Table 6 ). The weights of the following organs were (or tended to be) reduced by 10 and 20 mg/kg of VNP40101M on days 15, 29, 31, or 43: liver, kidney, adrenal gland, thymus, pituitary, spleen, testes, epididymis, and ovaries. The lung weights were increased by 10 and 20 mg/kg of VNP40101M . The magnitude of the organ weight changes induced by 10 and
FIGURE 1
Body weights from different treatment groups of rats treated with various doses of VNP40101M , given intravenously once daily for 5 consecutive days. VNP40101M treatment was initiated on day 1, and the rats were monitored for 15, 29, or 43 days. Six rats treated with 10 mg/kg of VNP40101M were intended to be followed for 43 days. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on this day for providing time-control values. Accordingly, the treatment groups for day 43 results were 0, 1, and 3 mg/kg. The sample size for each group was 3-10/sex/group, and the speci c sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05, compared to control group. The same results are presented in Table 4 . Note. VNP40101M treatment was initiated on day 1, and the rats were monitored for 15, 29, or 43 days. Six rats treated with 10 mg/kg of VNP40101M were intended to be followed for 43 days. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on this day for providing time-control values. Accordingly, the treatment groups for day 43 results were 0, 1, and 3 mg/kg. The sample size for different groups is listed in Table 1 .
The results are presented as mean § SEM. ¤ p < :05, compared to control group. The same results are presented in Figure 1 .
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FIGURE 2
Serum levels of total protein, albumin, and globulin from different groups of rats treated with various doses of VNP40101M . VNP40101M was given intravenously once daily for 5 consecutive days, starting on day 1, and the rats were euthanized on days 15, 29, or 43 for serum chemistry and other determinations. Six rats treated with 10 mg/kg of VNP40101M were intended to be euthanized on day 43. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on day 31 for time-control values. The treatment groups at various time points are: day 15 D 0, 1, 3, 10, and 20 mg/kg (i.e., all treatment groups); day 29 D 0, 3, and 10 mg/kg; day 31 D 0 and 10 mg/kg; and day 43 (or day 31) D 0, 1, and 3 mg/kg. The sample size for each group was 3-10/sex/group, and the speci c sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05 and ¤¤ p < :01, compared to control group. The same results are presented in Table 5 . Note. VNP40101M was given intravenously once daily for 5 consecutive days, starting on day 1, and the rats were euthanized on days 15, 29, or 43. Six rats treated with 10 mg/kg of VNP40101M were intended to be euthanized on day 43. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on day 31 for time-control values. The sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05 and ¤¤ p < :01, compared to control group. The same results are presented in Figures 2 to 4.
FIGURE 3
Red blood cell counts, hemoglobin levels, and hematocrit values from different groups of rats treated with various doses of VNP40101M . VNP40101M was given intravenously once daily for 5 consecutive days, starting on day 1, and the rats were euthanized on days 15, 29, or 43 for serum chemistry and other determinations. Six rats treated with 10 mg/kg of VNP40101M were intended to be euthanized on day 43. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on day 31 for time-control values. The treatment groups at various time points are: day 15 D 0, 1, 3, 10, and 20 mg/kg (i.e., all treatment groups); day 29 D 0, 3, and 10 mg/kg; day 31 D 0 and 10 mg/kg; and day 43 (or day 31) D 0, 1, and 3 mg/kg. The sample size for each group was 3-10/sex/group, and the speci c sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05 and ¤¤ p < :01, compared to control group. The same results are presented in Table 5 .
FIGURE 4
White blood cell counts and percent neutrophils, lymphocytes, and monocytes from different groups of rats treated with various doses of VNP40101M . VNP40101M was given intravenously once daily for 5 consecutive days, starting on day 1, and the rats were euthanized on days 15, 29, or 43 for serum chemistry and other determinations. Six rats treated with 10 mg/kg of VNP40101M were intended to be euthanized on day 43. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on day 31 for time-control values. The treatment groups at various time points are: day 15 D 0, 1, 3, 10, and 20 mg/kg (i.e., all treatment groups); day 29 D 0, 3, and 10 mg/kg; day 31 D 0 and 10 mg/kg; and day 43 (or day 31) D 0, 1, and 3 mg/kg. The sample size for each group was 3-10/sex/group, and the speci c sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05 and ¤¤ p < :01, compared to control group.
The same results are presented in Table 5 .
FIGURE 5
Organ weights (g) affected by VNP40101M , given intravenously once daily for 5 days, in rats. VNP40101M treatment was initiated on day 1, and the rats were euthanized on days 15, 29, or 43 for determination of organ weight. Six rats treated with 10 mg/kg of VNP40101M were intended to be euthanized on day 43. However, due to their poor clinical condition, these rats were euthanized for humane reasons on day 31. Six control rats were also euthanized on day 31 for time-control values. The treatment groups at various time points are: day 15 D 0, 1, 3, 10, and 20 mg/kg (i.e., all treatment groups); day 29 D 0, 3, and 10 mg/kg; day 31 D 0 and 10 mg/kg; and day 43 (or day 31) D 0, 1, and 3 mg/kg. The sample size for each group was 3-10/sex/group, and the speci c sample size is listed in Table 1 . The results are presented as mean § SEM. ¤ p < :05 and ¤¤ p < :01, compared to control group. The same results are presented in Table 6 .
20 mg/kg of VNP40101M were generally dose-related. Comparable results were obtained with the relative organ weights (relative to the brain weights).
Gross Necropsy
There were no necropsy ndings in rats treated with 1 mg/kg of VNP40101M . Red discoloration (hemorrhage) of the mesenteric lymph nodes in the lung; clear, pink or red uid within the thoracic cavity; and red discoloration of the lungs were observed in 1/40 to 2/40 rats treated with 3 mg/kg of VNP40101M (Table 3) . Red discoloration (hemorrhage) of the mesenteric lymph nodes in the lung; small thymuses (lymphoid depletion and/or necrosis); and clear, pink or red uid within the thoracic were observed in rats treated with 10 and 20 mg/kg of VNP40101M . The incidences were dose-related. Furthermore, the presence of thoracic cavity uid occurred on days 29 to 31 in the 10-mg/kg group, and on day 15 in the 20-mg/kg group. Once again, this direct relationship between the dose and the onset of effects was consistent with the pattern of reduction in the body weight and serum chemistry parameters (i.e., total protein, albumin, and globulin).
Histopathology
Several treatment-related microscopic effects, which occurred mildly and with low incidences at 1 mg/kg, to a greater degree at 3 mg/kg, and mostly at 10 and 20 mg/kg (Table 3) , were observed. These effects were lymphoid necrosis and depletion in the thymus as well as increased incidence (when compared to normal rats) of the following observations: mesenteric lymph node hemorrhage, lymphoid depletion in the Liver mesenteric lymph nodes, lymphoid depletion in the spleen, ne wisps of eosinophilic material within alveolar spaces of the lung (designated as alveolar edema), nonspeci c vascular congestion (hypostatic congestion, with focally ectatic capillary vessels), alveolar histiocytosis (consisting of clusters of large foamy intraalveolar macrophages), inconspicuous/sporadic vascular thrombi, and mild erythroid hyperplasia (increased numbers of erythrocyte precursors) of the bone marrow. The increased incidences of essentially all of these effects were dose-related.
Toxicology Studies of VNP40101M in Dogs Mortality and Unscheduled Euthanasia
No mortality occurred at 0.3 and 1 mg/kg. Both dogs treated with 3 mg/kg were euthanized on day 8, for humane reasons, due to their poor clinical condition (Table 7) .
Clinical Signs
There were no clinical signs in dogs treated with 0.3 and 1 mg/kg of VNP40101M that were in addition to those observed in the vehicle group, other than occasional inappetence (Table 7) . Dogs treated with 3 mg/kg showed reduced activity and dehydration on day 8 prior to euthanasia, in addition to inappetence.
Body Weight
Slight body weight losses (by »0.4 kg) were observed in both dogs in the 0.3 and 1 mg/kg groups of the 15-day experiment. However, there were no body weight changes in dogs treated with 1 mg/kg, when compared to dogs treated with vehicle, in the 50-day experiment. For the 3-mg/kg group, the body weight on day 8 was similar to the predose values. However, any body weight loss in the 3-mg/kg group could not be reliably determined because the dogs were euthanized on day 8.
Clinical Pathology
VNP40101M at 0.3 mg/kg did not affect any serum chemistry or hematological parameters. In the 1-mg/kg group of the 15-day experiment, VNP40101M induced a transient decrease (occurred on day 8 only) in WBC counts from a predose value of » 8 £ 10 3 /¹l to »3 £ 10 3 /¹l ( p < :05). Analysis of the relative differential WBC counts revealed decreased percent neutrophils and increased percent lymphocytes. However, VNP40101M also did not affect any serum chemistry or hematological parameters in the 1-mg/kg group of the 50-day experiment. VNP40101M at 3 mg/kg slightly increased alkaline phosphatase (from a predose value of »60 IU/l to »127 IU/l in both dogs, p < :05) and signi cantly decreased WBC counts (from a predose value of »11 £ 10 3 /¹l to »0.1 £ 10 3 /¹l in both dogs, p < :01) on day 8, prior to euthanasia. Analysis of the relative differential WBC counts revealed a reduction in percent neutrophils and lymphocytes.
Gross Necropsy
One or more of the following effects were observed during necropsy examination performed on day 15 in the dogs treated with 0.3 and 1 mg/kg (the incidences are shown in Table 7 ): enlarged spleens, red discoloration of the stomach and duodenum, red lesion in the ileum, and/or small thymuses. Small thymuses were also observed in both dogs treated with 3 mg/kg after euthanasia on day 8. Interestingly, no gross gastrointestinal abnormality could be observed in the 3-mg/kg dogs, which may be because these dogs were euthanized on day 8 because of their poor clinical condition and the GI abnormality might have been developed beyond day 8.
Histopathology
No treatment-related abnormality was observed in dogs treated with 1 mg/kg of VNP40101M following histopathological evaluation performed on day 47. There was no histopathological evaluation of tissues at the day 15 necropsy or in dogs euthanized on day 8 due to their poor clinical condition.
DISCUSSION
The objective of these studies was to systematically investigate the toxicological effects of VNP40101M , given IV once daily for 5 consecutive days, in rats and dogs. This daily £5 dosing schedule was chosen based on previous antitumor ef cacy studies in animals (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) . The previous animal ef cacy studies showed that, although VNP40101M induced antitumor activity with a single dose and multiple doses, multiple small doses can maintain the same antitumor ef cacy with less toxicity, when compared to the equivalent dose administered as a single dose. Therefore, we intend to investigate the safety and antitumor ef cacy in cancer patients using this dosing schedule, and these toxicology studies are a prerequisite for the initiation the clinical studies with this dosing regimen.
The doses for the current rodent toxicology study were chosen, based on previous preliminary studies that investigated the toxicity of VNP40101M at a wide dose range from 0 to 60 mg/kg in small sample sizes of two to four rats. The doses for this study was chosen such that three different doses were investigated: the dose that induced little or no treatment-related effects (i.e., low effect level or LOEL); the dose that induced either some effects but not of toxicological signi cance, or toxicity but the toxicity was reversible (i.e., the maximum tolerated dose or MTD); and the dose that induced signi cant toxicity (i.e., toxic dose). The investigation of these doses helps to determine the safety of VNP40101M and understand the types of toxicity associated with VNP40101M . The present rodent study indicated that 1 mg/kg was the LOEL,¸3 mg/kg was the MTD, and 10 to 20 mg/kg were not tolerated.
The toxicity induced at 10 mg/kg of VNP40101M was delayed, as re ected by mortality or poor clinical condition occurring on days 29 and 30, and the reduction in WBC counts being progressively worse during days 15 to 31 at 10 mg/kg. The delayed toxicity was not due to prolonged presence of VNP40101M in the body, because tissue distribution study in rats using radioactive-labeled VNP40101M indicated a lack of signi cant amount of radioactivity in the body by day 7 (Almassian et al. 2001) . Rather, the delayed toxicity was likely due to VNP40101M damaging DNA, via the 1-(3-cytosinyl), 2-(1-guanyl ) ethane G-C crosslinkage, and inhibiting various DNA repair enzymes including O 6 -alkylguanine-DNA alkyltransferase, via carbamoylation. Systemic toxicity as a result of DNA damage is generally delayed, as observed in this study, because most cell death normally occurs days after DNA damage. This is especially true for VNP40101M , because VNP40101M induces carbamoylation, by generating methyl isocyanate (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) . Carbamoylation inhibits apoptosis (via the inhibition of caspases), and apotosis is the cause of slightly damaged cells to commit to cell suicide. The early phase of toxicity induced by DNA damaging agents is usually due to cell suicide.
VNP40101M reduced WBC count, which may be due to the myelosuppression effect of VNP40101M , a common toxicity among cytotoxic agents (Oliverio 1973) . However, unlike the broad and severe myelosuppression effects of nitrosoureas and other cytotoxic agents (Oliverio 1973) , the myelosuppression induced by VNP40101M is mild and selective to WBC. This may be related to VNP40101M inducing high yields of the G-C DNA crosslink with minimal therapeutically irrelevant DNA lesions (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) . VNP40101M at high doses also damaged the lymphatic system, as evidenced by hemorrhage of the mesenteric lymph nodes in the lung, lymphoid depletion and necrosis in the thy-mus, and an increased incidence of lymphoid depletion in the spleen. The weights of the liver, kidney, adrenal gland, pituitary, spleen, testes, epididymis, and ovaries were (or tended to be) reduced at toxic doses of VNP40101M . Although VNP40101M has been shown to distribute broadly in the body according to tissue distribution study using radioactive-labeled VNP40101M (Almassian et al. 2001) , there were no obvious treatment-related toxicity (according to clinical pathology, gross necropsy, and histopathology ) in these organs. Therefore, the weight reduction may be indirectly induced due to dehydration. The fatal effects at¸10 mg/kg of VNP40101M were undoubtedly related to the pulmonary toxicity, because gross necropsy of rats that died or were euthanized (because of poor clinical condition) indicated hemorrhage of the mesenteric lymph nodes in the lung, as well as clear, pink or red uid within the thoracic cavity. Pulmonary toxicity was further supported by histopathological ndings in other rats. These ndings include increased incidences of alveolar edema, vascular congestion, alveolar histiocytosis in histopathology, and related clinical signs (polypnea, chromorhinorrhea, chromodacryorrhea , and staining). Both gross and microscopic pulmonary toxicity was also observed in rats treated with 3 mg/kg; however, the incidence was much lower than at the two higher doses (»7-30% vs. 100%). For rats treated with 1 mg/kg, there were no gross pulmonary changes, although a low incidence of mild histopathologic changes were observed in the lung. The pulmonary toxicity may be caused by the active and unstable species, 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine, generated by the interaction of VNP40101M with the strong and unstable base, oxygen free radicals, that are readily available in the lung. Although small thymuses (lymphoid depletion and/or necrosis) were also observed in rats that died or were euthanized, these effects are not considered to be fatal and were also observed in rats that survived until their sacri ce.
For the canine toxicology study, the doses were chosen based on the results from the rodent toxicology study, such that the LOEL, MTD, and toxic doses (according to mg/surface area [Freireich et al. 1966 ], see Table 1 ) that were observed in rats were chosen, for comparative purposes. Accordingly, the doses chosen were 0.3 mg/kg (equivalent to 1 mg/kg, or the LOEL, in rats), 1 mg/kg (equivalent to »3 mg/kg, or the MTD, in rats), and 3 mg/kg (equivalent to »10 mg/kg, or the toxic dose, in rats). The results indicate that the LOEL, MTD, and toxic dose levels that had been observed in rats were generally comparable in dogs, with exceptions that were related to the sensitivity of the GI system of dogs. Speci cally, VNP40101M at 0.3 mg/kg (equivalent to the LOEL in rats) did not induce any effects in dogs, except for some GI effects (i.e., red lesion in the ileum) and the associated effects (inappetence and slight body weight loss). The GI effects in dogs, but not in rats, may be due to a possible differential sensitivity of these two animal species to VNP40101M , a phenomenon that has previously been observed with another cytotoxic agent Triapine (Lee, Noveroske, and Almassian 2000) . Other effects were also observed, but these effects may not be directly related to VNP40101M treatment, because there was a lack of correlation between the incidence and the dose. Specically, enlarged spleens were observed and they may be a reaction to the blood volume reduction due to multiple blood sampling. Small thymuses were observed, but they may be related to stress. For dogs treated with 1 mg/kg, VNP40101M induced the same GI effects, as in dogs treated with 0.3 mg/kg. Additionally, a transient reduction in WBC counts, a nding that is consistent with the results from the rodent study, was also observed. For 3 mg/kg (equivalent to the toxic dose levels in rats), VNP40101M was also toxic to dogs, as re ected by the poor clinical condition of these dogs that required euthanasia for humane reasons prior to study completion. The cause of the poor clinical condition could not be determined because, other than small thymus, there were no abnormalities observed during gross necropsy and no tissues were evaluated histopathologically. Please note that, in dogs treated with 0.3 or 1 mg/kg of VNP40101M , the following gross necropsy abnormalities were observed on day 15: enlarged spleens, red discoloration of the stomach and duodenum, red lesion in the ileum (female at 0.3 mg/kg and both dogs at 1 mg/kg dogs), and small thymuses (female at 0.3 mg/kg). However, no treatment-related abnormality was observed with gross necropsy and histopathology performed on day 47 in dogs treated at the same dose of VNP40101M , indicating that all treatment effects that occurred at around day 15 were transient and/or recoverable.
The toxicological pro le in rats and dogs observed in the current study differs from the acute toxicological pro le (i.e., expressed during the rst 7 days after administration) of higher doses of VNP40101M observed in a previous study (Almassian et al. 2001) . The acute toxicological pro le, which was induced by¸30 mg/kg of VNP40101M administered IV either as a single dose or once daily for 5 consecutive days in rats and dogs, included increases in serum hepatic enzymes; decreases in red and white blood cell counts, and related indices; hemorrhage-related foci in enteric tissues, heart, kidneys, and lung; and mortality. It was not surprising that at extreme high doses, the acute toxicity was nonselective and involved multiple organs, when compared to the low-dose effects of involving more selectively the lung, the lymphatic system, the GI tract (in dogs), or the WBC counts. VNP40101M , like other cytotoxic agents and especially the alkylating agents, has a very narrow margin of safety. Specically, the maximum antitumor activity of VNP40101M has been shown to be¸6 mg/kg (or¸18 mg/m 2 , according to Freireich's conversion [Freireich et al. 1966] ) in mice, when given as multiple doses (Penketh, Shyam, and Sartorelli 2000; Shyam et al. 1996) . This maximum tolerated dose is also the MTD observed in the current investigation. Therefore, VNP40101M , like other cytotoxic agents, is expected to be eventually used in combination with other anticancer therapy (e.g., with other cytotoxic agents, radiation, surgery, etc.) for achieving antitumor ef cacy at lower doses than that to be used as a single-agent therapy.
In conclusion, VNP40101M , when given IV once daily for 5 consecutive days, has a LOEL of 1 mg/kg, a MTD of 3 mg/kg, and toxic doses at¸10 mg/kg in rats. The primary toxicity of VNP40101M was pulmonary toxicity and mortality. VNP40101M had similar LOEL, MTD, and toxic doses in dogs, except that dogs were sensitive to the GI effects of VNP40101M. The MTD in rats and dogs are equivalent to the therapeutic dose, indicating the VNP40101M has a very narrow margin of safety.
